Pharmaceutical Executive-03-01-2017

With big data one of the hot healthcare topics of the moment, we gauge pharma’s response to the hype to see if the industry is poised to take advantage of the promise of advanced analytics.

Amid the push for a more intelligent and predictive supply chain, is it imperative for pharma companies to advance with their supply chain digitization strategies now-or is there still time to “wait and see?”

No longer just hype, investing in big data is the path to the future for pharma, even if big returns aren't a direct result.

Facing mixed market signals, biotech companies look to rise above the fray in advancing new-wave discoveries to the clinical finish line.

Attack on treaties and imports threatens international operations.

How integrating next-generation sequencing data can advance efforts in immuno-oncology research.

A look at how pharma and biotech interim management has evolved in the last 20 years.

Click the title above to open the Pharmaceutical Executive March 2017 issue in an interactive PDF format.

With a population of just 4.7 million and a landmass smaller than the state of Indiana, the republic of Ireland stands as an unlikely pharmaceutical manufacturing powerhouse.